Clinical trial
Preferred Treatment of Type 1.5 Diabetes
NCT00194896 · University of Washington, Other · Completed
Key facts
| NCT number | NCT00194896 |
|---|---|
| Title | Preferred Treatment of Type 1.5 Diabetes |
| Official title | Rosiglitazone Intervention Study in Patients With Type 1.5 Diabetes |
| Lead sponsor | University of Washington, Other |
| Collaborators | Seattle Institute for Biomedical and Clinical Research GlaxoSmithKline Industry |
| Status | Completed |
| Study type | Interventional |
| Conditions | Type 2 Diabetes Mellitus |
| Intervention type | Drug |
| Interventions | rosiglitazone, glyburide |
| Enrollment | 64 |
| Start date | Feb 1, 2000 |
| Primary completion | Sep 1, 2008 |
| Completion | Dec 1, 2008 |
| First posted | Sep 19, 2005 |
| Last update posted | Mar 29, 2018 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: